Filing Flows › Evofem Biosciences (EVFM) › Q4 2024
Evofem Biosciences (EVFM) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 24, 2025
Evofem Biosciences (EVFM) reported revenue of $7.1M for the fourth quarter 2024 (Q4 2024), +47% from a year earlier and +58% from the quarter before. Operating margin was -14.1%, net loss $3.0M (42.8% of revenue).
Evofem Biosciences, Q4 2024: revenue $7.1M (+47% year over year), operating margin -14.1%, net loss $3.0M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.1M | +58% | +47% |
| Operating profit | −$1.0M | — | — |
| Net earnings | −$3.0M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $7.1M in Q4 2024, up 47% year over year and up 58% from the previous quarter.
Operating costs exceeded revenue by $1.0M, an operating margin of -14.1%. Total costs fell 1% while revenue rose 47%. The fastest-growing cost line was Cost of revenue (+58%). The quarter ended with a net loss of $3.0M, wider than the previous quarter's $2.4M loss. Net interest and other expense of $2.0M was the main reason.
Operating cash flow was −$2.4M. Non-cash charges added back $323K of depreciation and amortization and $188K of share-based compensation.
Questions
What was Evofem Biosciences' revenue in the fourth quarter 2024?
Evofem Biosciences (EVFM) reported revenue of $7.1M for the fourth quarter 2024 (Q4 2024), +47% from a year earlier and +58% from the quarter before.
Was Evofem Biosciences profitable in the fourth quarter 2024?
Operating loss was $1.0M (-14.1% of revenue) and net loss $3.0M.
Source: Evofem Biosciences 10-K on SEC EDGAR.